ATE422498T1 - Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems - Google Patents

Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems

Info

Publication number: ATE422498T1
Authority: AT; Austria
Prior art keywords: aüindole; tetrahydro; diseases; treatment; nervous system
Prior art date: 2001-03-13

Application number

AT02732459T

Other languages

English (en)

Inventor

Paul Hebeisen

Patrizio Mattei

Marc Muller

Hans Richter

Stephan Roever

Sven Taylor

Original Assignee

Hoffmann La Roche

Vernalis Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-13

Filing date

2002-03-06

Publication date

2009-02-15

2002-03-06 Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche

2009-02-15 Application granted granted Critical

2009-02-15 Publication of ATE422498T1 publication Critical patent/ATE422498T1/de

Links

210000003169 central nervous system Anatomy 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Addiction (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT02732459T 2001-03-13 2002-03-06 Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems ATE422498T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0106177.9A GB0106177D0 (en)	2001-03-13	2001-03-13	Piperazine derivatives

Publications (1)

Publication Number	Publication Date
ATE422498T1 true ATE422498T1 (de)	2009-02-15

Family

ID=9910578

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02732459T ATE422498T1 (de)	2001-03-13	2002-03-06	Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems

Country Status (20)

Country	Link
US (1)	US6844345B2 (de)
EP (1)	EP1370561B1 (de)
JP (1)	JP4230225B2 (de)
KR (1)	KR100618748B1 (de)
CN (1)	CN1245405C (de)
AR (1)	AR035945A1 (de)
AT (1)	ATE422498T1 (de)
AU (1)	AU2002304833B2 (de)
BR (1)	BR0208111A (de)
CA (1)	CA2438596C (de)
DE (1)	DE60231107D1 (de)
ES (1)	ES2320739T3 (de)
GB (1)	GB0106177D0 (de)
GT (1)	GT200200048A (de)
MX (1)	MXPA03008338A (de)
PA (1)	PA8540801A1 (de)
PE (1)	PE20021043A1 (de)
UY (1)	UY27204A1 (de)
WO (1)	WO2002072584A2 (de)
ZA (1)	ZA200306613B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6762132B1 (en) *	2000-08-31	2004-07-13	Micron Technology, Inc.	Compositions for dissolution of low-K dielectric films, and methods of use
BR0311970A (pt)	2002-06-19	2005-03-29	Biovitrum Ab	Novos compostos, seu uso e preparação
CL2004000826A1 (es)	2003-04-25	2005-03-04	Pfizer	Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
ATE525354T1 (de) *	2004-05-03	2011-10-15	Janssen Pharmaceutica Nv	Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
US7622466B2 (en) *	2005-11-18	2009-11-24	Hoffman-La Roche Inc.	Azaindole-2-carboxamide derivatives
ES2333672T3 (es)	2005-12-09	2010-02-25	F. Hoffmann-La Roche Ag	Derivados de amida triciclica para tratamiento de obesidad.
JP5528699B2 (ja)	2006-05-16	2014-06-25	武田薬品工業株式会社	縮合複素環化合物およびその用途
JP5520051B2 (ja)	2007-11-15	2014-06-11	武田薬品工業株式会社	縮合ピリジン誘導体およびその用途
EP2254886B1 (de) *	2008-03-28	2016-05-25	Nerviano Medical Sciences S.r.l.	3,4-dihydro-2h-pyrazino[1,2-a]indol-1-on derivate als kinase inhibitoren, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen
WO2011071136A1 (ja)	2009-12-11	2011-06-16	アステラス製薬株式会社	線維筋痛症治療剤
US20130143812A1 (en) *	2010-05-27	2013-06-06	Sekisui Medical Co., Ltd.	Anti-inflammatory drug
US20130267500A1 (en)	2010-09-01	2013-10-10	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
SG11201405328SA (en)	2012-03-16	2014-11-27	Vitae Pharmaceuticals Inc	Liver x receptor modulators
ES2607113T3 (es)	2012-03-16	2017-03-29	Vitae Pharmaceuticals, Inc.	Moduladores de los receptores X del hígado
CA2880682A1 (en) *	2012-08-06	2014-02-13	F. Hoffmann-La Roche Ag	Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
EP2981538B1 (de) *	2013-04-02	2017-08-02	F. Hoffmann-La Roche AG	Piperazin[1,2-a-]indol-1-one und [1,4-]diazepin[1,2-a-]indol-1-on
WO2015066344A1 (en)	2013-11-01	2015-05-07	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists and compositions and methods of use
CN106317058B (zh) *	2016-08-17	2018-10-02	广东省微生物研究所	化合物dichotocejpin A及其制备方法和在制备治疗糖尿病药物中的应用
JOP20190239A1 (ar)	2017-04-19	2019-10-09	Neurocrine Biosciences Inc	مركبات مثبطة لـ vmat2 وتركيبات منها
WO2019131902A1 (ja)	2017-12-27	2019-07-04	武田薬品工業株式会社	腹圧性尿失禁および便失禁の治療薬
CN117586171A (zh) *	2022-08-12	2024-02-23	长春金赛药业有限责任公司	吲哚类衍生物、药物组合物及其在中枢神经领域的应用
WO2026006356A1 (en) *	2024-06-25	2026-01-02	Vanderbilt University	6-(pyrimidin-5-yl)-3,4-dihydropyrazino[l,2-a]imdol-l(2h)-one mcl-1 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3317524A (en)	1965-02-04	1967-05-02	American Home Prod	Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
CA1247547A (en)	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
CA1270837A (en)	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
CA1328881C (en)	1984-12-21	1994-04-26	Pierre Barbier	Process for the manufacture of oxetanones
CA2035972C (en)	1990-02-23	2006-07-11	Martin Karpf	Process for the preparation of oxetanones
US5274143A (en)	1991-07-23	1993-12-28	Hoffmann-La Roche Inc.	Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0572863A1 (de) *	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
AU3831495A (en) *	1994-10-20	1996-05-15	American Home Products Corporation	Indole derivatives useful as serotonergic agents
US5854245A (en) *	1996-06-28	1998-12-29	Merck & Co., Inc.	Fibrinogen receptor antagonists
US6004996A (en)	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
CA2340056C (en)	1998-08-14	2007-01-09	F. Hoffmann-La Roche Ag	Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt)	1998-08-14	2004-08-31	Hoffmann La Roche	Composicoes farmaceuticas contendo inibidores da lipase e quitosano
GB9902047D0 (en) *	1999-01-29	1999-03-17	Cerebrus Ltd	Chemical compounds XI
WO2002010169A1 (en) *	2000-07-31	2002-02-07	F. Hoffmann-La Roche Ag	Piperazine derivatives

2001
- 2001-03-13 GB GBGB0106177.9A patent/GB0106177D0/en not_active Ceased
2002
- 2002-03-06 DE DE60231107T patent/DE60231107D1/de not_active Expired - Lifetime
- 2002-03-06 CA CA002438596A patent/CA2438596C/en not_active Expired - Fee Related
- 2002-03-06 MX MXPA03008338A patent/MXPA03008338A/es not_active Application Discontinuation
- 2002-03-06 BR BR0208111-3A patent/BR0208111A/pt not_active IP Right Cessation
- 2002-03-06 JP JP2002571500A patent/JP4230225B2/ja not_active Expired - Fee Related
- 2002-03-06 EP EP02732459A patent/EP1370561B1/de not_active Expired - Lifetime
- 2002-03-06 WO PCT/EP2002/002443 patent/WO2002072584A2/en not_active Ceased
- 2002-03-06 ES ES02732459T patent/ES2320739T3/es not_active Expired - Lifetime
- 2002-03-06 AT AT02732459T patent/ATE422498T1/de not_active IP Right Cessation
- 2002-03-06 CN CNB028062876A patent/CN1245405C/zh not_active Expired - Fee Related
- 2002-03-06 KR KR1020037011901A patent/KR100618748B1/ko not_active Expired - Fee Related
- 2002-03-06 AU AU2002304833A patent/AU2002304833B2/en not_active Ceased
- 2002-03-07 US US10/092,751 patent/US6844345B2/en not_active Expired - Fee Related
- 2002-03-07 PA PA20028540801A patent/PA8540801A1/es unknown
- 2002-03-11 AR ARP020100877A patent/AR035945A1/es not_active Application Discontinuation
- 2002-03-12 UY UY27204A patent/UY27204A1/es not_active Application Discontinuation
- 2002-03-12 GT GT200200048A patent/GT200200048A/es unknown
- 2002-03-12 PE PE2002000197A patent/PE20021043A1/es not_active Application Discontinuation
2003
- 2003-08-25 ZA ZA200306613A patent/ZA200306613B/en unknown

Also Published As

Publication number	Publication date
KR100618748B1 (ko)	2006-08-31
GB0106177D0 (en)	2001-05-02
GT200200048A (es)	2002-11-15
DE60231107D1 (de)	2009-03-26
KR20030080255A (ko)	2003-10-11
AR035945A1 (es)	2004-07-28
ZA200306613B (en)	2004-11-25
CA2438596C (en)	2008-07-08
WO2002072584A3 (en)	2003-01-03
CN1245405C (zh)	2006-03-15
EP1370561A2 (de)	2003-12-17
PE20021043A1 (es)	2002-11-19
JP2004532823A (ja)	2004-10-28
US6844345B2 (en)	2005-01-18
MXPA03008338A (es)	2003-12-11
BR0208111A (pt)	2004-03-02
JP4230225B2 (ja)	2009-02-25
UY27204A1 (es)	2002-09-30
PA8540801A1 (es)	2005-02-04
CA2438596A1 (en)	2002-09-19
WO2002072584A2 (en)	2002-09-19
CN1529706A (zh)	2004-09-15
AU2002304833B2 (en)	2006-05-04
US20020169163A1 (en)	2002-11-14
EP1370561B1 (de)	2009-02-11
ES2320739T3 (es)	2009-05-28

Legal Events

Date

Code

Title

Description

2009-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1370561

Country of ref document: EP

2011-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60231107D1 (de)	2009-03-26	Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60218493D1 (de)	2007-04-12	Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60316538D1 (de)	2007-11-08	Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de)	2009-10-15	Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE551340T1 (de)	2012-04-15	Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60239558D1 (de)	2011-05-05	Kombinationen für die behandlung von immun-entzündlichen erkrankungen
DE602004020072D1 (de)	2009-04-30	1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE345331T1 (de)	2006-12-15	Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60226702D1 (de)	2008-07-03	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60233414D1 (de)	2009-10-01	Kombinationen für die behandlung entzündlicher erkrankungen
DE69927823T2 (de)	2006-06-14	Hydrogel für die therapeutische behandlung von aneurysmas
ATE418554T1 (de)	2009-01-15	1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE286895T1 (de)	2005-01-15	Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE410430T1 (de)	2008-10-15	2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60204951D1 (de)	2005-08-11	Ccr5 antagonisten verwendbar für die behandlung von aids
DE60204466D1 (de)	2005-07-07	Integrinhemmer zur behandlung von augenkrankheiten
IL159344A0 (en)	2004-06-01	Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
ATE372118T1 (de)	2007-09-15	Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE60105614D1 (de)	2004-10-21	Oxazinochinolone für die behandlung viraler infektionen
DE50205466D1 (de)	2006-02-02	Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60016047D1 (de)	2004-12-23	Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60201440D1 (de)	2004-11-04	Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
ATE355283T1 (de)	2006-03-15	Isochroman verbindungen für die behandlung von cns-krankheiten
ATE391507T1 (de)	2008-04-15	S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
ATE357441T1 (de)	2007-04-15	Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne